223 related articles for article (PubMed ID: 32422491)
21. Leveraging β-Adrenergic Receptor Signaling Blockade for Improved Cancer Immunotherapy Through Biomimetic Nanovaccine.
Yang C; He Y; Chen F; Zhang F; Shao D; Wang Z
Small; 2023 Apr; 19(14):e2207029. PubMed ID: 36703529
[TBL] [Abstract][Full Text] [Related]
22. Engineering ApoE3-incorporated biomimetic nanoparticle for efficient vaccine delivery to dendritic cells via macropinocytosis to enhance cancer immunotherapy.
Zhou S; Huang Y; Chen Y; Liu S; Xu M; Jiang T; Song Q; Jiang G; Gu X; Gao X; Chen J
Biomaterials; 2020 Mar; 235():119795. PubMed ID: 32014739
[TBL] [Abstract][Full Text] [Related]
23. Multi-signaling pathway activation by pH responsive manganese particles for enhanced vaccination.
Lv X; Huang J; Min J; Wang H; Xu Y; Zhang Z; Zhou X; Wang J; Liu Z; Zhao H
J Control Release; 2023 May; 357():109-119. PubMed ID: 36738971
[TBL] [Abstract][Full Text] [Related]
24. Unprecedented Chiral Nanovaccines for Significantly Enhanced Cancer Immunotherapy.
Liu H; Xie Z; Zheng M
ACS Appl Mater Interfaces; 2022 Sep; 14(35):39858-39865. PubMed ID: 36007113
[TBL] [Abstract][Full Text] [Related]
25. Acidity-responsive polyphenol-coordinated nanovaccines for improving tumor immunotherapy
Qiu H; Wang S; Huang R; Liu X; Li L; Liu Z; Wang A; Ji S; Liang H; Jiang BP; Shen XC
Biomater Sci; 2024 Jun; 12(12):3175-3192. PubMed ID: 38742916
[TBL] [Abstract][Full Text] [Related]
26. Clickable amino acid derivative tuned self-assembly of antigen and adjuvant for cancer immunotherapy.
He X; Yang L; Su H; Lin S; Qi D; Chen H; Qu Y; Liu L; Feng X
J Control Release; 2021 Sep; 337():306-316. PubMed ID: 34311025
[TBL] [Abstract][Full Text] [Related]
27. Vaccination of TLR7/8 Agonist-Conjugated Antigen Nanoparticles for Cancer Immunotherapy.
Wang N; Zhang G; Zhang P; Zhao K; Tian Y; Cui J
Adv Healthc Mater; 2023 Sep; 12(22):e2300249. PubMed ID: 37016572
[TBL] [Abstract][Full Text] [Related]
28. Polymer nanoparticles for cross-presentation of exogenous antigens and enhanced cytotoxic T-lymphocyte immune response.
Song C; Noh YW; Lim YT
Int J Nanomedicine; 2016; 11():3753-64. PubMed ID: 27540289
[TBL] [Abstract][Full Text] [Related]
29. Ferroptosis and Necroptosis Produced Autologous Tumor Cell Lysates Co-Delivering with Combined Immnoadjuvants as Personalized
Shi W; Feng W; Li S; Cui Y; Liu S; Jiang H; Liu Y; Zhang H
ACS Nano; 2023 Aug; 17(15):14475-14493. PubMed ID: 37466500
[TBL] [Abstract][Full Text] [Related]
30. Mannan-decorated pathogen-like polymeric nanoparticles as nanovaccine carriers for eliciting superior anticancer immunity.
Xu Y; Ma S; Zhao J; Chen H; Si X; Huang Z; Yu Z; Song W; Tang Z; Chen X
Biomaterials; 2022 May; 284():121489. PubMed ID: 35364489
[TBL] [Abstract][Full Text] [Related]
31. CD47KO/CRT dual-bioengineered cell membrane-coated nanovaccine combined with anti-PD-L1 antibody for boosting tumor immunotherapy.
Liu S; Wu J; Feng Y; Guo X; Li T; Meng M; Chen J; Chen D; Tian H
Bioact Mater; 2023 Apr; 22():211-224. PubMed ID: 36246666
[TBL] [Abstract][Full Text] [Related]
32. Cascade Cytosol Delivery of Dual-Sensitive Micelle-Tailored Vaccine for Enhancing Cancer Immunotherapy.
Jiang D; Mu W; Pang X; Liu Y; Zhang N; Song Y; Garg S
ACS Appl Mater Interfaces; 2018 Nov; 10(44):37797-37811. PubMed ID: 30360105
[TBL] [Abstract][Full Text] [Related]
33. "Minimalist" Nanovaccine Constituted from Near Whole Antigen for Cancer Immunotherapy.
Wang K; Wen S; He L; Li A; Li Y; Dong H; Li W; Ren T; Shi D; Li Y
ACS Nano; 2018 Jul; 12(7):6398-6409. PubMed ID: 29927574
[TBL] [Abstract][Full Text] [Related]
34. A Visible Codelivery Nanovaccine of Antigen and Adjuvant with Self-Carrier for Cancer Immunotherapy.
Dong X; Liang J; Yang A; Qian Z; Kong D; Lv F
ACS Appl Mater Interfaces; 2019 Feb; 11(5):4876-4888. PubMed ID: 30628437
[TBL] [Abstract][Full Text] [Related]
35. Functionalized multifunctional nanovaccine for targeting dendritic cells and modulation of immune response.
El-Sayed N; Korotchenko E; Scheiblhofer S; Weiss R; Schneider M
Int J Pharm; 2021 Jan; 593():120123. PubMed ID: 33278496
[TBL] [Abstract][Full Text] [Related]
36. RNA cancer vaccines: developing mRNA nanovaccine with self-adjuvant property for cancer immunotherapy.
Zhang H; Xia X
Hum Vaccin Immunother; 2021 Sep; 17(9):2995-2998. PubMed ID: 33945399
[TBL] [Abstract][Full Text] [Related]
37. Functional characterization of biodegradable nanoparticles as antigen delivery system.
Petrizzo A; Conte C; Tagliamonte M; Napolitano M; Bifulco K; Carriero V; De Stradis A; Tornesello ML; Buonaguro FM; Quaglia F; Buonaguro L
J Exp Clin Cancer Res; 2015 Oct; 34():114. PubMed ID: 26444005
[TBL] [Abstract][Full Text] [Related]
38. Nanovaccine loaded with poly I:C and STAT3 siRNA robustly elicits anti-tumor immune responses through modulating tumor-associated dendritic cells in vivo.
Luo Z; Wang C; Yi H; Li P; Pan H; Liu L; Cai L; Ma Y
Biomaterials; 2015 Jan; 38():50-60. PubMed ID: 25457983
[TBL] [Abstract][Full Text] [Related]
39. Extending antigen release from particulate vaccines results in enhanced antitumor immune response.
Kapadia CH; Tian S; Perry JL; Sailer D; Christopher Luft J; DeSimone JM
J Control Release; 2018 Jan; 269():393-404. PubMed ID: 29146244
[TBL] [Abstract][Full Text] [Related]
40. Combination of GNRs-PEI/cGAMP-laden macrophages-based photothermal induced in situ tumor vaccines and immune checkpoint blockade for synergistic anti-tumor immunotherapy.
Jin C; Zhang Y; Zhang G; Wang B; Hua P
Biomater Adv; 2022 Feb; 133():112603. PubMed ID: 35525760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
